Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
Sobota
J T
JT
Chugai-Upjohn, Inc., Chicago, Ill.
D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D001803:Blood Transfusion; D004305:Dose-Response Relationship, Drug; D004906:Erythrocyte Count; D017707:Erythrocyte Transfusion; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006400:Hematocrit; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications* / Q000628:therapy; D015337:Multicenter Studies as Topic; D006435:Renal Dialysis; D012156:Reticulocytes; D014481:United States
D006454:Hemoglobins; D004921:Erythropoietin